Novartis' Rhapsido Gains EU Regulatory Support, but Valuation and LOE Risks Linger

What happened

Novartis received a positive CHMP opinion for remibrutinib (Rhapsido) in chronic spontaneous urticaria, advancing its oral BTK inhibitor toward EU approval as part of the immunology pipeline. This milestone is consistent with the company's strategy to bolster growth from newer assets like Rhapsido, which is already noted in recent filings as a high-value component. However, the DeepValue master report rates Novartis as a 'POTENTIAL SELL' due to a premium valuation at $144, with concerns over Entresto's loss of exclusivity eroding sales. While this regulatory step reduces near-term uncertainty for Rhapsido, it does not materially alter the financial projections or offset the significant generic headwinds highlighted in the report. Investors should remain critical, as the stock's 47% rally over 12 months prices in such pipeline successes, leaving limited margin of safety if core brands underperform or margins compress from acquisitions.

Implication

First, the CHMP opinion lowers regulatory risk for Rhapsido, potentially contributing modestly to future sales in a competitive urticaria market. Second, however, Rhapsido is a smaller asset in a portfolio dominated by larger growth drivers like Kisqali and Kesimpta, limiting its impact on overall revenue. Third, the stock's premium multiple of ~19.5x P/E already embeds expectations for pipeline milestones, reducing the upside from this news. Fourth, the core investment thesis hinges on offsetting Entresto's rapid erosion with priority brand growth, a challenge unchanged by this development. Fifth, therefore, investors should view this as a confirming event rather than a catalyst for re-rating, emphasizing the need for cautious position sizing amid looming margin and execution risks.

Thesis delta

The positive CHMP opinion for Rhapsido aligns with management's pipeline guidance and does not shift the fundamental investment thesis. Key risks—such as sales growth falling below 5% or core margins dipping under 38% due to LOE and acquisition costs—remain unchanged, and the stock's valuation continues to reflect limited upside from current levels. This news reinforces the existing narrative but offers no material delta to warrant a change in the 'POTENTIAL SELL' rating.